This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yanardag, R Articles by Karabulut-Bulan, O Search for Related Content PubMed PubMed Citation Articles by Yanardag, R Articles by Karabulut-Bulan, O Social Bookmarking                         What's this?

Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats

Refiye Yanardag, Department of Chemistry, Faculty of Engineering, Istanbul University, 34320 Avcilar, Istanbul, Turkey, yanardag{at}istanbul.edu.tr

O Ozsoy-Sacan

Department of Chemistry, Faculty of Engineering, Istanbul University, Avcilar, Istanbul, Turkey

S Bolkent

Department of Biology, Faculty of Science, Istanbul University, Vezneciler, Istanbul, Turkey

H Orak

Organic Division, Department of Chemistry, Faculty of Engineering, Istanbul University, Avcilar, Istanbul, Turkey

O Karabulut-Bulan

Department of Biology, Faculty of Science, Istanbul University, Vezneciler, Istanbul, Turkey

Metformin is a biguanide derivate used as an oral hypoglycaemic drug in diabetics. The aim of this study was to examine the histological and biochemical effects of metformin in streptozotocin (STZ)-treated rats. The animals were rendered diabetic by intraperitoneal injection of 65 mg/kg STZ. Fourteen days later, metformin was given at 25 mg/kg by gavage, daily for 28 days, to STZdiabetic rats and a control group. In the STZ-diabetic group, some degenerative changes were observed by light microscopic examination. But the degenerative changes were decreased in the STZ-diabetic group given metformin. In the STZ-diabetic group, blood glucose levels, serum alanine and aspartate transaminase (ALT and AST) activities, total lipid levels, and sodium and potassium levels increased, while body weight, serum magnesium levels and liver glutathione (GSH) levels decreased. In the STZ-diabetic group given metformin, blood glucose levels, serum ALT and AST activities, total lipid, and sodium and potassium levels decreased, and liver GSH and serum magnesium levels increased. As a result of all the morphological and biochemical findings obtained, it was concluded that metformin has a protective effect against the hepatotoxicity produced by STZ diabetes.

Key Words: diabetes mellitus • hepatotoxicity • liver • metformin • rat

Human & Experimental Toxicology, Vol. 24, No. 3, 129-135 (2005)
DOI: 10.1191/0960327104ht507oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Elia, V. Sander, C.G. Luchetti, M.E. Solano, G. Di Girolamo, C. Gonzalez, and A.B. Motta The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice Mol. Hum. Reprod., August 1, 2006; 12(8): 475 - 481. [Abstract] [Full Text] [PDF]